Eisai Pricing For Lecanemab Reflects Concern With Medicare ‘Sustainability,’ ‘Giving Back,’ Firm Says
Executive Summary
Despite internal modeling indicating lecanemab offers a ‘societal value’ of around $37,600 per year, the company has decided on a list price of around $26,500 annually to moderate the impact on Medicare and patients.
You may also be interested in...
ICER’s New President On What She Wants From Industry – And From Medicare Price Negotiations
In an interview, Sarah Emond talks about why she is ‘worried’ about cell and gene therapy, when ICER might revise its assessment of obesity drugs, and how CMS could build a reliable and transparent Medicare price negotiation program.
How Much Delay In Alzheimer’s Disease Progression Is Clinically Meaningful?
US FDA agrees with Eisai/Biogen that half a point change in cognitive scale, which sponsor says means a five month delay in decline, is a clinically meaningful benefit. But others contend the treatment effect is small and does not outweigh risk of brain bleeds.
Leqembi’s FSS Pricing Meets ICER’s Cost-Effectiveness Threshold; VA Requiring Coverage With Evidence
Eisai/Biogen Alzheimer’s treatment isn’t actually on the VA formulary, but Leqembi’s Federal Supply Schedule price, coming in at just over $20,000 annually, could address spending concerns.